← All trials
NCT07015996
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 18, 2026
- Primary completion
- Sep 16, 2028
- Completion date
- Sep 16, 2028
- First posted
- Jun 11, 2025
- Last posted
- Oct 30, 2025
- Enrollment
- 62
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Rho, Inc.Collaborator
- Immune Tolerance NetworkCollaborator
- PPDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.